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Atherosclerotic vascular disease is one of the great epidemics of the twenty-first 
Century.1 Decades before its clinical manifestation, endothelial dysfunction (ED) marks the 
beginning of an insidious disease process, which silently progresses up until a point where it 
can only be slowed but not reversed. ED is induced by a variety of mediators, some of which 
are known and related to established cardiovascular risk factors such as smoking, 
dyslipidemia, hypertension, diabetes and aging, while others are presently unknown. As ED 
develops the balance between anti-atherogenic and pro-atherogenic factors in slowly shifted 
in favor of the latter. In this multifactorial process, reduced bioavailability of nitric oxide 
(NO) plays a pivotal role. NO, a free radical gas with an in vivo half-life of a few seconds, is 
synthesized primarily from endothelial NO synthase (eNOS), which is activated in response 
to flow-induced shear stress, cytokines, and hormones.2 In vitro, NO inhibits the expression of 
cell adhesion molecules such as VCAM-1, ICAM and E-selectin as well as the secretion of 
pro-inflammatory cytokines such as Il-6 and Il-8, thus preventing monocyte attraction and 
adhesion.3 In line with these findings, early studies using eNOS knockout mice demonstrated 
an increase in atherosclerotic lesions in these animals.4, 5 In contrast, however, more recent 
studies revealed that eNOS knockout mice may under certain circumstances also be relatively 
protected from the development of atherosclerosis, and that transgenic overexpression of 
eNOS in fact may accelerate atherogenesis.6, 7 While the exact mechanism remains unclear, it 
is highly likely that in the inflammatory microenvironment of the dysfunctional endothelium 
and developing atherosclerotic lesion, increased oxidative stress leads to an immediate 
chemical reaction of NO with superoxide resulting in the generation of peroxynitrite, thereby 
reducing both the bioavailability of NO as well as increasing post-transcriptional 
modifications of vital proteins and tyrosine residues. Together with a plethora of other 
mediators, the dysbalance of NO and reactive oxygen species (ROS) leads to the propagation 
of ED resulting in leukocyte adhesion and diapedesis, migration and proliferation of vascular 
smooth muscle cells, and enhanced platelet-vessel wall interaction. When LDL-laden 
macrophages accumulate in the vessel wall, a “fatty streak” develops marking the first visible 
manifestation of atherosclerosis. Left untreated and further exposed to pro-atherogenic 
stimuli, such lesions may advance and eventually result in the development and progression 
of overt atherosclerotic disease with its clinical complications such as angina, acute 
myocardial infarction, and stroke. 
 While overt atherosclerotic disease (especially when clinically symptomatic) is 
comparatively easy to see, its future development in an asymptomatic population is hard to 
foresee. Indeed, at the early stage of the cascade when solely ED is present, individuals 
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usually do not complain of symptoms; yet identifying these potential “patients” intuitively 
appears important in order to interrupt the atherogenic process and prevent further vascular 
damage. Flow-mediated dilation (FMD) of the brachial artery was first described in the late 
1980s;8 it is predominantly dependent on endothelium-derived NO,9 and is therefore widely 
used as a readout of endothelial (dys-)function, mainly in the research setting.10 For example, 
intravenous infusion of recombinant high-density lipoprotein (HDL) cholesterol improves 
FMD in hypercholesterolemic patients.11 Similarly, treatment with ACE inhibitors increased 
FMD in hypertensive patients.12 FMD posses several advantages as compared to more 
invasive measurement such as coronary vasoreactivity testing with intracoronary infusion of 
acetylcholine. Indeed, FMD correlates well with coronary endothelial function,13 is non-
invasive, comparatively inexpensive, and becomes abnormal early in the course of 
atherogenesis (i.e., at the stage of endothelial dysfunction, hence long before structural 
changes occur). As such, FMD represents an interesting candidate procedure for 
cardiovascular risk stratification, and several studies have been conducted in order to examine 
the prognostic value of FMD in patients at high risk for or with established cardiovascular 
disease. For example, patients with coronary artery disease (as assessed by exercise 
myocardial perfusion imaging) had lower FMD than those without CAD,14 and in patients 
with single-vessel CAD who underwent stent implantation, FMD was impaired in those who 
developed restenosis as compared to those who did not.15 In patients undergoing vascular 
surgery, a low preoperative FMD was predictive of a postoperative event during the following 
1.2 years.16 In a recent prospective study in 2792 elderly adults (aged 72 to 98 years), FMD 
predicted future cardiovascular events (without, however, adding much to the prognostic 
accuracy of traditional cardiovascular risk scores or factors).17 
Collectively these investigations suggest a potential prognostic value of FMD. 
Common to these studies, however, is the fact that they were conducted in populations at high 
risk of or with already established atherosclerotic disease – hence in a situation where the 
horse is already out of the barn. In their present study, Halcox and colleagues18 went back 
several years on the atherosclerotic time line and prospectively investigated the prognostic 
value of FMD on carotid artery intimal-media thickness (IMT) progression in middle aged 
individuals at low to intermediate cardiovascular risk without clinical signs of established 
atherosclerotic vascular disease. Surprisingly, neither established cardiovascular risk factors 
nor Framingham Risk Score (FRS), but only FMD was associated with average annual 
progression of IMT over an observational period of 6.2 years. The association between FMD 
and IMT progression remained significant even after patients with antihypertensive drugs and 
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statins were omitted from the analysis; this is of importance both because these patients could 
be considered to be at an increased risk for atherosclerosis and because of the known 
influence of these classes of drugs on FMD. No association was found between FMD and 
IMT at baseline, which, as the authors point out, is not too surprising since IMT is generally 
viewed as a measure of the cumulative structural atherosclerotic vascular burden; in contrast, 
FMD reflects both chronic long-term as well as early dysfunctional changes, the latter of 
which most probably representing the more important part in this pre-clinical population.  
While these data indeed imply that FMD may predict progression of atherosclerosis, a 
couple of questions remain. Unexpectedly, a trend towards an inverse relationship was 
observed between LDL cholesterol and IMT progression, and patients with the most rapid 
progression of atherosclerosis had lower waist circumference, lower triglyceride levels, and 
higher HDL cholesterol. Given the well established association of LDL cholesterol and of the 
metabolic syndrome with the development of atherosclerotic cardiovascular disorders, these 
findings may indicate that the individuals studied in this trial may not represent a “normally” 
advancing atherosclerotic study population. The authors, in contrast, argue that this 
association most probably occurred through a type I error, i.e. the erroneous assumption of a 
statistical difference (or trend) when in truth there is none. Indeed, the validity of the authors’ 
study population is underscored by the association of baseline LDL cholesterol and baseline 
IMT, as well as by fact that the association between FMD and IMT progression remained 
significant even after adjusting for the conventional cardiovascular risk factors (both when 
entered separately or as FRS). However, the above named discrepancies with established 
epidemiological findings require clarification.  
A drawback of the current study and potentially of the methodology itself is the rather 
low positive predictive value of FMD of only 35% for predicting rapid progression of 
atherosclerosis (as compared to a negative predictive value of 83%). This is in line with 
earlier observations of both the authors and others indicating that the negative predictive 
value of endothelial function testing is most reliable (i.e., a good FMD is most likely 
associated with less progression of atherosclerosis).14, 19  
Some methodological concerns also have to be taken into consideration when 
interpreting the data of Halcox and colleagues. Measurement of brachial artery FMD is 
challenging because of a variety of potential confounders as well as a intraindividual variation 
to repeated measurements. In the present study, potential confounding with food intake, 
drugs, exercise, or ambient temperature were meticulously taken care of by the authors. One 
important quality criterion of FMD measurement is the observed intra-examinator difference; 
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Halcox et al. report an overall coefficient of variation for repeated measurement of <11%, 
which appears acceptable (especially in view of the long follow-up of the study patients) 
although a lower variation in the range of <5% is usually desirable.20 Furthermore, the authors 
found not only FMD, but also brachial artery diameter to be associated with IMT progression, 
which is in line with a previous prospective study in the elderly.17 This is important from a 
methodological standpoint, as an increase in baseline diameter will result in a decrease in 
FMD (by the way FMD is calculated); it is thus tempting to speculate that the observed 
association of IMT progression with reduced FMD may be “artificial” and merely reflects the 
increase in brachial artery diameter (as a result of positive remodeling in the setting of 
advancing atherosclerosis). While the absence of  an association with carotid artery diameter 
and IMT progression argues somewhat against this interpretation, further studies are clearly 
needed to address this issue. 
In summary, the work of Halcox and colleagues in this issue of Circulation18 adds 
good quality data to the growing evidence that brachial artery FMD measurement may be of 
prognostic value. As with all good studies, several open questions remain; these issues as well 
the inherent limitations of the methodology itself demonstrate that FMD is not yet ready for 
prime time as a reliable prognostic indicator. The validity and power of this method to 
establish itself as a tool for risk stratification will critically depend on the ability to objectify 
and reproduce measurements; hence, efforts are needed to overcome the above-mentioned 
methodological limitations and to standardize high-quality protocols for brachial artery FMD 
measurement. In addition, further long-term large-scale studies are needed to substantiate the 
authors’ findings, to investigate whether FMD is able to truly predict the occurrence of 
clinical events (and not only a progression of the “surrogate” marker IMT), to demonstrate 
how FMD measurement integrates with other cardiovascular risk assessment tools and 
biomarkers, and to focus on whether improving FMD will result in improved clinical 
outcome. 
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